Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 1998;80:108-109; doi:10.1136/hrt.80.2.108
Copyright © 1998 BMJ Publishing Group Ltd & British Cardiovascular Society

Heart 1998;80:108-109 ( August )

Editorial

Diabetes and coronary artery disease: time to stop taking the tablets?

The first 150 words of the full text of this article appear below.

Patients with diabetes develop accelerated coronary artery disease and are 10 to 20 times overrepresented among those suffering from acute myocardial infarction.1,2 Mortality in the year following infarction is up to twice that of non-diabetics, and coronary artery disease remains the most common single cause of death in diabetic patients.3

Despite the wide prevalence of diabetes and its high rate of coronary artery disease, it remains unclear how diabetic patients with this complication should best be treated. An emerging concern is that standard treatments for the million or so non-insulin dependent diabetic patients in the UK may be contributing to the considerable morbidity and mortality from cardiovascular disease. These patients are most commonly treated with oral hypoglycaemic agents, usually sulphonylureas. Concern about such treatment, particularly sulphonylureas, has been expressed intermittently for nearly 30 years.4-7 Such concerns have become increasingly focused recently because of improved understanding of the molecular mechanisms of action of sulphonylureas, . . . [Full text of this article]
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Stevens, R. J., Coleman, R. L., Adler, A. I., Stratton, I. M., Matthews, D. R., Holman, R. R. (2004). Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66. Diabetes Care 27: 201-207 [Abstract] [Full Text]  
  • Reffelmann, T, Klues, H G, Hanrath, P, Schwarz, E R (2002). Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease. Heart 87: 54-60 [Abstract] [Full Text]  
  • Gibbons, R. J., Chatterjee, K., Daley, J., Douglas, J. S., Fihn, S. D., Gardin, J. M., Grunwald, M. A., Levy, D., Lytle, B. W., O'Rourke, R. A., Schafer, W. P., Williams, S. V., Ritchie, J. L., Gibbons, R. J., Cheitlin, M. D., Eagle, K. A., Gardner, T. J., Garson, A. Jr, Russell, R. O., Ryan, T. J., Smith, S. C. Jr (1999). ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 33: 2092-2197 [Full Text]  
  • EDWARDS, R J, RAKHIT, R D, MARBER, M S (1999). Diabetes and coronary artery disease: time to stop taking the tablets. Heart 81: 674-674 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Show me all >>